Shepherd Kaplan Krochuk’s Vertex Pharmaceuticals VRTX Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-1,964	Closed	-$205K	–	423
2015 Q3	$205K	Sell	1,964 -792	-29%	-$102K	0.05%	265
2015 Q2	$340K	Sell	2,756 -680	-20%	-$85.7K	0.06%	218
2015 Q1	$405K	Hold	3,436	–	–	0.07%	197
2014 Q4	$408K	Hold	3,436	–	–	0.07%	238
2014 Q3	$386K	Buy	3,436 +220	+7%	+$20.9K	0.05%	253
2014 Q2	$304K	Hold	3,216	–	–	0.03%	347
2014 Q1	$227K	Buy	+3,216	New	+$255K	0.03%	420

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Shepherd Kaplan Krochuk's VRTX Position: Q4 2015 in Review

Shepherd Kaplan Krochuk sold out of Vertex Pharmaceuticals (VRTX) in Q4 2015, closing a stake of 1,964 shares — an estimated $205K sold.

Shepherd Kaplan Krochuk first reported a position in VRTX in Q1 2014 and held it in 7 quarters. The position peaked at $408K in Q4 2014. 517 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

Shepherd Kaplan Krochuk reported no remaining Vertex Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Shepherd Kaplan Krochuk sold 1,964 Vertex Pharmaceuticals shares in Q4 2015, an estimated $205K.
Shepherd Kaplan Krochuk first reported a position in Vertex Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Shepherd Kaplan Krochuk's Vertex Pharmaceuticals position peaked at $408K in Q4 2014.
517 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Shepherd Kaplan Krochuk's 13F filing for Q4 2015, filed 16 Feb 2016.